Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade.
Owaki T, Iida T, Miyai Y, Kato K, Hase T, Ishii M, Ando R, Hinohara K, Akashi T, Mizutani Y, Ishikawa T, Mii S, Shiraki Y, Esaki N, Yamamoto M, Tsukamoto T, Nomura S, Murakami T, Takahashi M, Yuguchi Y, Maeda M, Sano T, Sassa N, Matsukawa Y, Kawashima H, Akamatsu S, Enomoto A. Owaki T, et al. Among authors: akamatsu s. Br J Cancer. 2024 Jul;131(2):372-386. doi: 10.1038/s41416-024-02734-3. Epub 2024 Jun 7. Br J Cancer. 2024. PMID: 38849479 Free PMC article.
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
Kobayashi T, Iwama S, Yamagami A, Izuchi T, Suzuki K, Otake K, Yasuda Y, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Nishio N, Mori S, Shimokata T, Sano T, Niimi K, Yoshikawa N, Akamatsu S, Ando Y, Akiyama M, Sone M, Ishii M, Arima H. Kobayashi T, et al. Among authors: akamatsu s. Cancer Immunol Immunother. 2024 Jun 4;73(8):146. doi: 10.1007/s00262-024-03733-2. Cancer Immunol Immunother. 2024. PMID: 38833157 Free PMC article.
Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.
Nomura M, Ohuchi M, Sakamoto Y, Kudo K, Yaku K, Soga T, Sugiura Y, Morita M, Hayashi K, Miyahara S, Sato T, Yamashita Y, Ito S, Kikuchi N, Sato I, Saito R, Yaegashi N, Fukuhara T, Yamada H, Shima H, Nakayama KI, Hirao A, Kawasaki K, Arai Y, Akamatsu S, Tanuma SI, Sato T, Nakagawa T, Tanuma N. Nomura M, et al. Among authors: akamatsu s. Nat Commun. 2023 Dec 13;14(1):8095. doi: 10.1038/s41467-023-43630-3. Nat Commun. 2023. PMID: 38092728 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 38703018
This Issue 30-10.
Akamatsu S. Akamatsu S. Int J Urol. 2023 Oct;30(10):807. doi: 10.1111/iju.15297. Int J Urol. 2023. PMID: 37794850 No abstract available.
Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.
Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M. Tanegashima T, et al. Among authors: akamatsu s. J Immunol. 2024 Jul 1;213(1):23-28. doi: 10.4049/jimmunol.2300308. J Immunol. 2024. PMID: 38758119 Free PMC article.
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.
Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, Gangadharannambiar P, Wang Y, Akamatsu S, Beltran H, Cox M, Crea F, Daugaard M, Dong X, Haffner M, He H, Jachetti E, Kyprianou N, Li B, Ong CE, Rickman DS, Sen T, Zhu HH, Zoubeidi A, Gleave ME. Wang Y, et al. Among authors: akamatsu s. Epigenomics. 2024;16(17):1129-1132. doi: 10.1080/17501911.2024.2391729. Epub 2024 Sep 3. Epigenomics. 2024. PMID: 39225130
A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide.
Tashiro Y, Akamatsu S, Ueno K, Kamoto T, Terada N, Hida T, Kurahashi R, Kamba T, Saito A, Lee T, Morita S, Kobayashi T. Tashiro Y, et al. Among authors: akamatsu s. Int J Clin Oncol. 2024 Oct;29(10):1564-1573. doi: 10.1007/s10147-024-02597-x. Epub 2024 Aug 17. Int J Clin Oncol. 2024. PMID: 39153094 Free PMC article.
A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity.
Fujiwara H, Kubota M, Hidaka Y, Ito K, Kawahara T, Kurahashi R, Hattori Y, Shiraishi Y, Hama Y, Makita N, Tashiro Y, Hatano S, Ikeuchi R, Nakashima M, Utsunomiya N, Takashima Y, Somiya S, Nagahama K, Fujimoto T, Shimizu K, Imai K, Takahashi T, Sumiyoshi T, Goto T, Morita S, Kobayashi T, Akamatsu S. Fujiwara H, et al. Among authors: akamatsu s. Int J Clin Oncol. 2024 Oct;29(10):1574-1585. doi: 10.1007/s10147-024-02577-1. Epub 2024 Jul 19. Int J Clin Oncol. 2024. PMID: 39028395 Free PMC article.
363 results